Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Siltuximab in Multicentric Castleman's Disease
2010-022837-27Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siltuximab in multicentric angiofollicular lymphoid hyperplasia (MCD), sponsored by Janssen Pharmaceutical. Primary endpoints: Proportion of patients with adverse events and Maintenance of disease control in prior responders. Started Jul 2012; status: completed.
02
Drugs
siltuximab
03
Conditions
multicentric angiofollicular lymphoid hyperplasia (MCD)
Beyond the preview
Go deeper on 2010-022837-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022837-27.